<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893880</url>
  </required_header>
  <id_info>
    <org_study_id>CTP8</org_study_id>
    <nct_id>NCT00893880</nct_id>
  </id_info>
  <brief_title>A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis</brief_title>
  <official_title>A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-arm trial to evaluate the efficacy and safety of using gaseous nitric oxide to treat
      moderate to severe tinea pedis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cure (negative KOH and culture and no signs or symptoms), Effective treatment (negative KOH and culture and at most mild erythema or scaling), Negative mycology (negative KOH and culture).</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical and mycological effect of 1% gaseous nitric oxide (gNO) as a treatment for Tinea Pedis in the clinically evaluable population at the Test-of-Cure (TOC) evaluation (4 weeks post-treatment) according to the definitions below:</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical and mycological effect of the topical application of 1% gNO as confirmed by pre treatment positive culture and clinical signs and symptoms compared to 2 weeks post treatment outcomes according to definitions below:</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical and mycological effect of the topical application of 1% gNO as confirmed by pre treatment positive culture and clinical signs and symptoms compared to 1 week post treatment outcomes according to definitions below:</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of daily topical applications of 1% gNO as confirmed by methemoglobin levels and adverse events.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) 30min treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) 60min treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(2) 30min treatments over two consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(2) 60min treatments over two consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% gaseous Nitric Oxide blended in Oxygen</intervention_name>
    <description>1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive clinical findings (moderate to severe, indicated by a CSSS ≥ 6) for
             interdigital or bullous tinea pedis as determined by clinical examination (subjects
             with moccasin symptoms in addition to above may also be included at the discretion of
             the investigator).

          -  Written informed consent must be obtained from the subject.

          -  Must ≥ 18 years of age, unless local laws dictate otherwise.

          -  Must agree to avoid professional pedicures or application of any nail polish product
             or nail cosmetic to the toenails after the screening visit until the conclusion of the
             trial.

          -  Must not be pregnant or nursing, and if of childbearing potential, agree to take
             measures to avoid pregnancy during the study period

        Exclusion Criteria:

          -  Has a diagnosis of either psoriasis or eczema, in or immediately around the area under
             evaluation.

          -  Has a visual diagnosis, by the investigator, of onychomycosis at a level, which in the
             opinion of the investigator would compromise the integrity of the study.

          -  Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole-
             (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole,
             econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox
             olamine-(Loprox®, Medicis), tolnaftate, haloprogin), Zeasorb-AF , antibacterials and
             corticosteroids in the preceding 14 days of screening visit (Day 1), on or immediately
             around the area under evaluation.

          -  Use of oral or injectable systemic corticosteroids in the preceding 7 or 30 days
             respectively, of screening visit (Day 1)

          -  Use of systemic antifungals in the preceding 30 days of screening visit (Day1)
             including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen),
             fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®,
             Pedinol), butoconazole, terconazole, Potassium iodide)

          -  Has used any investigational drug(s) within 30 days preceding screening visit (Day 1)

          -  Is pregnant or is a nursing mother

          -  Is a woman of child bearing potential who is not using an adequate form of
             contraception (or abstinence)

          -  Is &lt; 18 years of age, unless local laws dictate otherwise.

          -  Is immunosuppressed (undergoing chemotherapy, neutropenia (PMNs , &lt; 500/mm3), HIV with
             CD4+ &lt; 200/mm3.

          -  Suffers from a condition, which, in the opinion of the medical investigator, would
             compromise his/her safety and / or the quality of the data. Such conditions may
             include collagen vascular disease, diabetes mellitus, Cushing's Disease, hematological
             malignancy, chronic mucocutaneous candidiasis or atopy STATISTICS This clinical
             evaluation is intended to demonstrate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mediprobe Research, Inc</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eureka Health Services</name>
      <address>
        <city>Ramsbury Site</city>
        <state>Nevis</state>
        <country>Saint Kitts and Nevis</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diversified Healthcare Solutions</name>
      <address>
        <city>Basseterre</city>
        <state>St. Kitts</state>
        <country>Saint Kitts and Nevis</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates</name>
      <address>
        <city>Basseterre</city>
        <state>St. Kitts</state>
        <country>Saint Kitts and Nevis</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Saint Kitts and Nevis</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Athletes Foot</keyword>
  <keyword>Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

